Impact of pharmaceutical regulation and policies on health system performance goals in Israel

Advances in Health Economics and Health Services Research

Volumn 22, Issue , 2010, Pages 77-101

  Sax, Philip ^a   Shmueli, Amir ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GLATIRAMER; IMATINIB; NEW DRUG; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG; RASAGILINE; TRASTUZUMAB; VERTEPORFIN;

BUDGET; CONSULTATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG ELUTING STENT; DRUG MARKETING; FINANCIAL MANAGEMENT; FUNDING; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; ISRAEL; LAW; LOWEST INCOME GROUP; MEDICAL SPECIALIST; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; RISK MANAGEMENT; TAX; ARTICLE; ECONOMICS; HEALTH CARE DELIVERY; LEGAL ASPECT; MANAGEMENT; MOTIVATION; PHARMACY; STANDARD;

COST CONTROL; DELIVERY OF HEALTH CARE; GOALS; HEALTH SERVICES ACCESSIBILITY; ISRAEL; PHARMACEUTICAL SERVICES; POLICY MAKING;

EID: 77954994087     PISSN: 07312199     EISSN: None     Source Type: Book Series    
DOI: 10.1108/S0731-2199(2010)0000022007     Document Type: Review

References (27)

1. Central Bureau of Statistics. (2007). National expenditure on health. Jerusalem (in Hebrew).
2. Dayan, A. (2007). Medicines in the "stocks". Zman HaRefuah, 15-21 (in Hebrew).
3. Eldar-Lissai, A., Shani, S., & Shvarts, S. (2006). Impact of parallel trade of pharmaceuticals on the Israeli health care system. Annual research report 2005-6. Israel National Institute of Health Policy & Health Services Research (in Hebrew).
4. Gress, S., Niebuhr, D., May, W., & Wasem, J. (2007). Reform of prescription drug reimbursement & pricing in the German social health insurance market. Pharmaco Economics, 25, 443-454. (Pubitemid 46849186)
5. Gross, R., Brammli-Greenberg, S., & Matzliach, R. (2005). Public opinions on the level of service & performance of the health system in 2003 in comparison with previous years. Myers-JDC Brookdale Institute (in Hebrew).
6. Gross, R., & Harrison, M. I. (2006). Responses of Israeli sickness funds to environmental change following the national health insurance law: Opening the black box. Health Policy, 76, 213-232. (Pubitemid 43330605)
7. Guiffrida, A., & Torgerson, D. (1997). Should we pay the patient? Review of financial incentives to enhance patients' compliance. British Medical Journal, 315, 703-707. (Pubitemid 27405824)
8. Guillen, A. M., & Cabiedes, L. (2003). Reforming pharmaceutical policies in the EU: A "penguin effect"? International Journal of Health Services, 33, 1-23.
9. Jacobzone, S. (2000). Pharmaceutical policies in OECD countries: Reconciling social and industrial goals. Labour market and social policy. Occasional Papers No. 4. OECD, Paris.
10. Lichtenberg, F. R. (1996). Do (more & better) drugs keep people out of hospitals? American Economic Review, 86, 384-398.
11. Lichtenberg, F. R. (2001). Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs, 20, 241-251. (Pubitemid 33710357)
12. Lofgren, H., & de Boer, R. (2004). Pharmaceuticals in Australia: Developments in regulation and governance. Social Science & Medicine, 58, 2397-2407. (Pubitemid 38471783)
13. Ministry of Health. (2006). Quality indicators for community health care in Israel. State of Israel Public Report 2003-5. Jerusalem (in Hebrew).
14. Ministry of Health. (2007). Regulation 72 for determination of timetable for product registration. State of Israel, Jerusalem (in Hebrew).
15. Rosen, B., & Goldwag, R. (2003). Health care systems in transition: Israel. In: S. Thomson & E. Mossialos (Eds), European observatory on health care systems. Copenhagen: WHO.
16. Sax, P. (1989). Availability & timing on new drugs in Israel: Analysis & international comparison. Journal of Clinical Pharmacology, 29, 967-974. (Pubitemid 20038074)
17. Sax, P. (2001). Changes in drug economy in Israel's health maintenance organizations in the wake of the national health insurance law. Israel Medical Association Journal, 3, 605-609. (Pubitemid 32878543)
18. Sax, P. (2005). Spending on medicines in Israel in an international context. Israel Medical Association Journal, 7, 286-291. (Pubitemid 40668148)
19. Sax, P. (2007). Sick funds and the Israel drug economy: Affordable medicines for whom? Pharma Israel Drug Bulletin, 77, 1-7.
20. Shani, S., Shemer, J., Luxembourg, O., & Siebzehner, M. (2001). Setting priorities for the adoption of health technologies on a national level - The Israeli experience. Health Policy, 54, 169-174.
21. Shmueli, A. (2008). Economic evaluation of the decisions of the Israeli public committee for updating the national list of health services in 2006/2007. Value in Health, 12, 202-206.
22. Shmueli, A., Achduth, L., & Sabag-Endeld, M. (2008). Financing the package of services during the first decade of the national health insurance law in Israel: Trends and issues. Health Policy, 87, 273-284.
23. Smith, S. W. (2007). Sidelining safety - The FDA's inadequate response to the IOM. New England Journal of Medicine, 357, 960-963. (Pubitemid 47367075)
24. State of Israel, Bureau of the Comptroller. (2007). Annual report, Vol. 57B. Jerusalem (in Hebrew).
25. Tal, O., Nir, A., Hakak, N., Bakshi, E., & Fire, G. (2006). Criteria for early adoption of medical technologies. Tel Hashomer: Gertner Institute for Epidemiology & Health Policy Research.
26. Vogel, D. (1998). The globalization of pharmaceutical regulation. Governance, 11, 1-22.
27. Zmora, I., Chernichovsky, D., & Shmueli, A. (2003). The Israeli capitation system. The Taub Centre for Social Policy Studies in Israel, Jerusalem (in Hebrew).